About RoosterBio
RoosterBio is a company based in Frederick (United States) founded in 2012 by Jon Rowley. RoosterBio has raised $38.41 million across 8 funding rounds from investors including HHS, Vanedge Capital and Bioeconomy Capital. RoosterBio operates in a competitive market with competitors including BioLife Solutions, Mesoblast, SanBio, Shanghai Doning Biotechnology and ArunA Bio, among others.
- Headquarter Frederick, United States
- Founders Jon Rowley
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Roosterbio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$38.41 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
HHS
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of RoosterBio
Unlock access to complete
Unlock access to complete
Funding Insights of RoosterBio
RoosterBio has successfully raised a total of $38.41M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RoosterBio
RoosterBio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Vanedge Capital and Bioeconomy Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested in US and Canadian companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment in life sciences innovation is facilitated by Dynamk Capital.
|
Locked | Locked | Locked |
Investor details for RoosterBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RoosterBio
Investment portfolio details for RoosterBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RoosterBio
Detailed financials for RoosterBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Roosterbio Comparisons
Peer comparison for RoosterBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RoosterBio
RoosterBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, Mesoblast, SanBio, Shanghai Doning Biotechnology and ArunA Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| Locked | Locked | Locked |
Regenerative cell medicines for neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Serum-free cell culture media is supplied to biopharmaceutical industries.
|
|
| Locked | Locked | Locked |
Neural exosome platform is developed for neurodegenerative disease therapeutics.
|
Detailed competitors of RoosterBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Roosterbio
Complete news archive for RoosterBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RoosterBio
RoosterBio was founded in 2012 and raised its 1st funding round 2 years after it was founded.
RoosterBio is headquartered in Frederick, United States. It is registered at Frederick, Maryland, United States.
Tim Kelly is the current CEO of RoosterBio.
RoosterBio is a funded company, having raised a total of $38.41M across 8 funding rounds to date.
RoosterBio was founded in 2012 and is headquartered in Frederick, United States. Operations center on the biotechnology sector, where human bone marrow-derived and adipose-derived mesenchymal stem cells are produced alongside specialized media formulations for cell expansion. Extracellular vesicles associated with these cells are also developed. The companys activities support stem cell research and therapeutic applications in a controlled manufacturing environment.
RoosterBio's top competitors include FabricNano, Prolific Machines and BioLife Solutions.
RoosterBio has 5 investors. Key investors include HHS, Vanedge Capital, Bioeconomy Capital, Dynamk Capital, and Maryland Stem Cell Research Fund.